MK-677 vs Sermorelin: What the Research Shows
MK-677 and Sermorelin side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider MK-677 if…
- you want an oral option with randomized human data: in obese men, MK-677 25 mg daily raised serum IGF-I by about 40% versus placebo over 8 weeks (a hormone outcome)[11]
- you are weighing trade-offs: in that trial an oral glucose tolerance test showed impairment of glucose homeostasis at 2 and 8 weeks[11]
- you want to see a negative human trial: in Alzheimer disease, MK-677 raised serum IGF-1 but was ineffective at slowing disease progression[13]
Consider Sermorelin if…
- you want human data in growth-hormone-deficient children, though uncontrolled: Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months (open-label, no control group).[12]
What they have in common
- Sermorelin's only FDA record is Geref, listed with marketing status Discontinued[14]
Spec comparison
Showing 9 of 10 fields where the two differ. PCAC vote, Jul 2026 are the same or both unknown.
| Field | MK-677 | Sermorelin |
|---|---|---|
| Class | Oral ghrelin agonist (not a peptide) | GHRH analog |
| Also called | ibutamoren | — |
| FDA status | Not FDA approved · research chemical | Compounded by prescription |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | No WADA record in our data | Prohibited by WADA (S2.2.4)Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. |
| Anti-doping detection | None reportedanti-doping literature, as of 2 Oct 2026 |
|
| Half-life | [half-life by route] | No published half-life foundPubMed search, 11 Oct 2026 |
| Evidence strength | [evidence grade] | Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 1992, PMID 1379256 |
| Human studies we summarised | [n] | 6 human (1 randomized or controlled) of 9 summarised |
| Typical study doses | [dose range] |
|
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
A secretagogue pill versus a GHRH injection
In a placebo-controlled sermorelin study in healthy older men, short-term subcutaneous GHRH reversed the age-related decreases in GH and IGF-I.[4]
A longer sermorelin study in older men found nightly injection left weight, DEXA measures of muscle and fat, and lipids unchanged.[6]
In MK-677's two-month trial in obese men, fat-free mass rose significantly on two different measurement methods.[11]
In a sermorelin study of young patients, mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr after 6 months and 7.2 cm/yr after 12 months.[12]
Route, status and sport rules
The sermorelin studies in the cache all use subcutaneous injection; the paediatric study gave it once daily.[12]
Sermorelin was once an approved drug and no longer is: the only FDA record is Geref, with marketing status discontinued.[14]
MK-677's largest trial in the cache, in Alzheimer's disease, reported no clinical effect on progression.[13]
Both are named in the same section of the prohibited list: sermorelin among the GHRH analogues and MK-677 among the secretagogues.[1]
In a sermorelin study in adults, upright row and shoulder press strength and abdominal crunch endurance improved, but not the other strength measures.[6]
Common questions
Is MK-677 better than sermorelin?
No trial compares them. MK-677 has a trial showing a rise in fat-free mass; sermorelin has paediatric data and a discontinued FDA record.[11]
Is sermorelin still FDA approved?
No. The one FDA record for it, Geref, is listed as discontinued, with no currently marketed sermorelin product found.[14]
Can you take MK-677 and sermorelin together?
No study combines them. The cached WADA list names both.[1]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 4Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
- 5Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
- 6Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
- 7PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: (ibutamoren[tiab] OR "MK-677"[tiab] OR MK0677[tiab]) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.The Journal of clinical endocrinology and metabolism · 1998PMID 9467542Accessed 2 Oct 2026
- 12Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
- 13Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.Neurology · 2008PMID 19015485Accessed 2 Oct 2026
- 14Drugs@FDA (openFDA) search: active ingredient "sermorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 15PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
Found an error? Report a correction.